EUVIMEDEUVIMED entdecken
Crossref

Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives

Carla Rognoni, Arianna Bertolani, Claudio Jommi

Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish · 2018

DOI: 10.1177/2284240318784289 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish, 2018. Verfasst von Carla Rognoni und 2 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Sandoz Italia Spa.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Förderung

  • Sandoz Italia Spa

Zitieren

APA

Rognoni, C., Bertolani, A., & Jommi, C. (2018). Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish. https://doi.org/10.1177/2284240318784289

Vancouver

Rognoni C, Bertolani A, Jommi C. Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish. 2018. doi:10.1177/2284240318784289

BibTeX
@article{Rognoni2018,
  author = {Rognoni, Carla and Bertolani, Arianna and Jommi, Claudio},
  title = {Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives},
  journal = {Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish},
  year = {2018},
  doi = {10.1177/2284240318784289}
}
Kostenlos starten →